“We believe a national RSV program is needed so all infants born in Australia have access to Beyfortus. A national program for next year’s RSV season will make it easier for parents and healthcare professionals to discuss infant eligibility, no matter where the child is born," said Regis Launay, the general manager of vaccines for Sanofi Australia and New Zealand. …
More states announce RSV programs as families call for national action
March 26, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
Georgia Forrest
New Stories
-
Prescription medicines at the centre of Trump’s 'Great Healthcare Plan'
January 18, 2026 - - Latest News -
Boehringer Ingelheim again recognised as a top employer across Australia and New Zealand
January 18, 2026 - - Latest News -
The quiet and steady privatisation of this critical public health program
January 18, 2026 - - Latest News -
AbbVie to consolidate Sydney operations with move to CBD headquarters
January 15, 2026 - - Latest News -
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News